Navigation Links
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Date:8/19/2007

p> Interim Consolidated Statements of Cash Flows

for the Six Months Ended June 30, 2007 and 2006 (unaudited)

(in thousands of US dollars)

Period from

Six months March 9, 1993(*)

ended June 30, to June 30,

2007 2006 2007

---------- ---------- ----------

CASH FLOWS FROM OPERATING ACTIVITIES:

Loss for the period (14,649) (7,291) (129,572)

Adjustments to reconcile loss to net cash

used in operating activities:

Depreciation and amortization 69 114 3,141

Linkage difference on restricted long-term (2) (4) (9)

deposits

Acquisition of in process research

and development -- -- 1,783

Gain on disposal of property and equipment (53) (25) (92)

Increase (decrease) in liability in

respect of employee severance obligations (49) 35 1,187

Impairment charges 95 -- 475

Gain from sales of investment securities -- -- (410)

Other income related to exchange of shares -- -- (100)

Loss from trading securities 48 -- 46

Stock option based compensation expenses 969 1,213 6,427

Stock appreciation rights compensation

expenses 565 -- 565

Gain on amounts funded in respect of

employee severance pay funds -- -- (92)

Deferred tax asset 48 -- --

Changes
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Biosciences Corporation announced today the enrollment and dosing at ... of the first patient in the ACE ( ... Phase 2 pivotal trial in patients with relapsed or ... novel, orally available, potent and highly selective small molecule ... (FLT3) inhibitor. The ACE study is designed to ...
(Date:12/11/2009)... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... appointment of Dr. Alan Warrander to the role ... Development. ,, "Dr. Warrander will be responsible for ... REOLYSIN(R)," said Dr. Brad Thompson, President and CEO ... design of a Phase 3 trial examining REOLYSIN ...
(Date:12/10/2009)... 10 Endologix, Inc. (Nasdaq: ELGX ... disorders, announced today that Dan Lemaitre, former President ... Board of Directors effective December 11, 2009. ... non-independent directors. ,, Franklin D. Brown, Chairman of ... Dan Lemaitre to the Endologix Board of Directors. ...
(Date:12/10/2009)... MISSISSAUGA, ON, Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences ... a life sciences product development company that identifies ... products at various stages of development, today provided ... result in the merger of Cytopia Ltd. into ... 5, 2009. The board of directors of Cytopia ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4
... /PRNewswire-FirstCall/,-- Cephalon, Inc., (Nasdaq: CEPH ) announced ... Human Use (CHMP) of the European,Medicines Agency has ... buccal tablet pain medication. In March 2007, Cephalon,submitted ... treatment of,breakthrough pain in adult cancer patients who ...
... quality, practice management and reimbursement content ... available through web-based delivery platform, DALLAS-FORT WORTH, Texas, ... and services to help accelerate,advancements in the treatment of ... delivery of healthcare,information, have joined forces to bring Oncology ...
... Jan. 24 Aton Pharma, Inc., ... that it has,launched an expanded, comprehensive ... and patient education resources, for the,dry ... Lacrisert is a unique preservative-free, once-daily*, ...
Other Biology Technology:Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 3Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 4Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 2Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 3Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 2Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 3
(Date:12/11/2009)... Malus orientalis species of wild apples that could ... the Middle East and Central Asia. A new study ... varieties from Georgia and Armenia with previously collected ... population and establishes a core collection that will make ... and research communities. , To identify and record the ...
(Date:12/11/2009)... Western Reserve University has granted an 18-month, exclusive ... portfolio of insulin analogs. The company must reach ... to obtain an exclusive license on therapies designed ... Diabetes is developing treatments that it hopes will ... rapidly growing insulin market. Insulin is a therapeutic ...
(Date:12/11/2009)... 4th edition of Springer,s classic reference and textbook Vogel ... A. McKusick Leadership Award. The prize, which recognizes Professor ... was presented to him at the 59th Annual Meeting ... October 2009 in Honolulu, Hawaii. , Motulsky is Professor ... of Washington in Seattle. One of the founding giants ...
Breaking Biology News(10 mins):Understanding apples' ancestors 2Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2New Hospitals Therapeutic Design Supports Healing Green Practices 60015 1New Hospitals Therapeutic Design Supports Healing Green Practices 60015 2New Hospitals Therapeutic Design Supports Healing Green Practices 60015 3New Hospitals Therapeutic Design Supports Healing Green Practices 60015 4Holiday Toy Safety 3A Tips to Protect Young Eyes 60011 1Holiday Toy Safety 3A Tips to Protect Young Eyes 60011 2Holiday Toy Safety 3A Tips to Protect Young Eyes 60011 3Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 1Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 2Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 3Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 4
... ways creates a sustained, partial correction to bleeding problems in ... with the development of gene therapy treatment for Hemophilia A, ... can cause serious internal bleeding in people. , Researchers at ... College of Medicine improved a vector -- a vehicle that ...
... concentration in the earth's atmosphere shows that a sharp rise ... evolutionary boost they needed to dominate the planet, according to ... author of a paper published Sept. 30 in the journal ... abundance of carbon 13, a byproduct of photosynthesis, in ...
... critical to the migratory success of many bird species. ... of migratory birds to orient to magnetic signals, researchers ... may be more complex than previously thought and that ... more than one mechanism. The work is reported in ...
Other Biology News:Gene therapy advance treats hemophilia in mouse models 2Gene therapy advance treats hemophilia in mouse models 3Oxygen increase caused mammals to triumph, researchers say 2Overbearing colored light may reveal a second mechanism by which birds interpret magnetic signals 2
... DNA Engine Dyad thermal cycler is ... (PCR). The chassis accommodates a variety ... assemblies), which hold different types and ... graphical programming with point-and-click navigation. Peltier ...
... IHC Select Immunophosphatase Secondary Detection System is ... Select Prediluted Primary Antibody reagents, which contain ... identification of antigens by light microscopy in ... Detection System may also be used with ...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
Biology Products: